Fundamental Analysis (Long term)
Open in Telegram
https://t.me/+Rn8RmYm0XMZTagXs I'm not a SEBI registered advisor,the information provided by me is for educational purposes only.You are responsible for all investment decisions,plz note that I dont provide any tips/stock suggestion.
Show moreπ Analytical overview of Telegram channel Fundamental Analysis (Long term)
Channel Fundamental Analysis (Long term) (@fundamental3) in the English language segment is an active participant. Currently, the community unites 44 973 subscribers, ranking 2 541 in the Economy & Finance category and 8 229 in the India region.
π Audience metrics and dynamics
Since its creation on Π½Π΅Π²ΡΠ΄ΠΎΠΌΠΎ, the project has demonstrated rapid growth, gathering an audience of 44 973 subscribers.
According to the latest data from 06 September, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by -188 over the last 30 days and by -7 over the last 24 hours, overall reach remains high.
- Verification status: Not verified
- Engagement rate (ER): The average audience engagement rate is 6.48%. Within the first 24 hours after publication, content typically collects 4.29% reactions from the total number of subscribers.
- Post reach: On average, each post receives 2 916 views. Within the first day, a publication typically gains 1 929 views.
- Reactions and interaction: The audience actively supports content: the average number of reactions per post is 5.
- Thematic interests: Content is focused on key topics such as margin, revenue, capacity, expansion, fy27.
π Description and content policy
The author describes the resource as a platform for expressing subjective opinions:
βhttps://t.me/+Rn8RmYm0XMZTagXs
I'm not a SEBI registered advisor,the information provided by me is for educational purposes only.You are responsible for all investment decisions,plz note that I dont provide any tips/stock suggestion.β
Thanks to the high frequency of updates (latest data received on 07 September, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Economy & Finance category.
44 973
Subscribers
-724 hours
-657 days
-18830 days
Data loading in progress...
Similar Channels
Tags Cloud
Incoming and Outgoing Mentions
---
---
---
---
---
---
Attracting Subscribers
September '26
September '26
+11
in 3 channels
August '26
+100
in 11 channels
Get PRO
July '26
+146
in 13 channels
Get PRO
June '26
+114
in 13 channels
Get PRO
May '26
+122
in 10 channels
Get PRO
April '26
+89
in 11 channels
Get PRO
March '26
+62
in 12 channels
Get PRO
February '26
+131
in 10 channels
Get PRO
January '26
+227
in 7 channels
Get PRO
December '25
+245
in 12 channels
Get PRO
November '25
+134
in 12 channels
Get PRO
October '25
+241
in 7 channels
Get PRO
September '25
+177
in 9 channels
Get PRO
August '25
+105
in 16 channels
Get PRO
July '25
+71
in 9 channels
Get PRO
June '25
+156
in 8 channels
Get PRO
May '25
+183
in 10 channels
Get PRO
April '25
+173
in 9 channels
Get PRO
March '25
+315
in 10 channels
Get PRO
February '25
+124
in 7 channels
Get PRO
January '25
+277
in 7 channels
Get PRO
December '24
+459
in 12 channels
Get PRO
November '24
+226
in 10 channels
Get PRO
October '24
+569
in 10 channels
Get PRO
September '24
+1 501
in 13 channels
Get PRO
August '24
+1 665
in 12 channels
Get PRO
July '24
+765
in 8 channels
Get PRO
June '24
+914
in 5 channels
Get PRO
May '24
+644
in 5 channels
Get PRO
April '24
+615
in 6 channels
Get PRO
March '24
+614
in 6 channels
Get PRO
February '24
+940
in 6 channels
Get PRO
January '24
+1 196
in 7 channels
Get PRO
December '23
+1 438
in 8 channels
Get PRO
November '23
+825
in 6 channels
Get PRO
October '23
+578
in 6 channels
Get PRO
September '23
+779
in 0 channels
Get PRO
August '23
+554
in 0 channels
Get PRO
July '23
+579
in 0 channels
Get PRO
June '23
+418
in 0 channels
Get PRO
May '23
+159
in 0 channels
Get PRO
April '23
+178
in 0 channels
Get PRO
March '23
+181
in 0 channels
Get PRO
February '23
+551
in 0 channels
Get PRO
January '23
+219
in 0 channels
Get PRO
December '22
+601
in 0 channels
Get PRO
November '22
+399
in 0 channels
Get PRO
October '22
+517
in 0 channels
Get PRO
September '22
+258
in 0 channels
Get PRO
August '22
+469
in 0 channels
Get PRO
July '22
+386
in 0 channels
Get PRO
June '22
+271
in 0 channels
Get PRO
May '22
+356
in 0 channels
Get PRO
April '22
+650
in 0 channels
Get PRO
March '22
+674
in 0 channels
Get PRO
February '22
+804
in 0 channels
Get PRO
January '22
+1 420
in 0 channels
Get PRO
December '21
+628
in 0 channels
Get PRO
November '21
+851
in 0 channels
Get PRO
October '21
+1 525
in 0 channels
Get PRO
September '21
+1 023
in 0 channels
Get PRO
August '21
+1 487
in 0 channels
Get PRO
July '21
+1 997
in 0 channels
Get PRO
June '21
+2 164
in 0 channels
Get PRO
May '21
+2 291
in 0 channels
Get PRO
April '21
+1 504
in 0 channels
Get PRO
March '21
+1 330
in 0 channels
Get PRO
February '21
+1 277
in 0 channels
Get PRO
January '21
+2 180
in 0 channels
Get PRO
December '20
+17 817
in 0 channels
| Date | Subscriber Growth | Mentions | Channels | |
| 07 September | 0 | |||
| 06 September | +4 | |||
| 05 September | +1 | |||
| 04 September | +2 | |||
| 03 September | +4 | |||
| 02 September | 0 | |||
| 01 September | 0 |
Channel Posts
IIFL FINANCE IN FOCUS
CNBC-TV18 EXCLUSIVE | SOURCES SAY
Blackstone Looks To Acquire Up To 20% Stake In IIFL Finance
Blackstone May Acquire Fairfax's Entire Stake In IIFL Finance
Fairfax Owns Around 13% Stake In IIFL Fin, 2% Was Picked Up By Global Fll In This Qtr
Blackstone May Acquire Additional 7-10% Stake In IIFL Finance Via Pref Issue
IIFL Finance & Fairfax May Also Be In Talks With Other PEs For Stake Sale
| 2 | MOREPEN LAB says
Looking At Higher Growth This Year With New CDMO Orders
EBITDA Margin Target: 15%+ To High Teens
CDMO Margins Are Higher Than API Business | 1 087 |
| 3 | Syrma SGS +6% Today
Mgmnt joined us on Friday
Key takeaways:
- Expect 50β70 Cr this year from the Elemaster JV, scalable to Scalable to 450-1000 Cr in 3-5 years
- JV has 12-13% margins, 200β300 bps higher than the core business
- Initial Investment at 55 Cr in the JV
On Guidance:
- Upgraded annual revenue growth target from 30% to 35%, could revise further post Q2
- EBITDA Margin guidance maintained at around 10.5% for FY27 | 2 973 |
| 4 | KSH makes winding wire that goes inside power transformers
Q1 FY27 revenue doubled to βΉ1,164 Cr because transformer OEMs are placing bigger orders as India builds grid and data centre capacity. Specialized wire for 765 kV and HVDC transformers now generates 75% of KSH revenue and grew 113% in Q1.
EBITDA per ton jumped 41% to βΉ93,000 because specialized wire carries better margins than standard grades. Capacity is expanding from 43,445 MT to 59,045 MT by March 2027
KSH work in specialized niche zone :)
India transformer market is roughly $3B in 2026 growing at 8 to 9% CAGR toward $5B by 2031. Grid modernization, renewable integration, and data centres pull demand at same time.
India needs 500 GW of renewable capacity by 2030 and has 157 GW under construction as of March 2026. Peak power demand projected to cross 400 GW by 2030.
Data centre power appetite could hit 13.56 GW by 2032. KSH sells winding wire to every major transformer maker serving these segments
BIS localization norms are redirecting imported standard winding wire toward Indian producers and KSH is positioned to absorb that shift. KSH also entered PEEK insulated wire for EV motors, with dedicated production line under installation for passenger car and bus programmes starting FY28 to FY29.
Export revenue jumped 76% in Q1 FY27 on wallet share gains with existing OEMs. Backward integrated copper recycling plant at Chakan went live August 2026 with 5,000 MT capacity.
Management targets βΉ180 to 190 Cr PAT by FY28 | 1 783 |
| 5 |  ANUPAM RASAYAN | SPECIALTY CHEMICALS β CDMO β PHARMA β ADVANCED MATERIALS
BUSINESS & GROWTH PLATFORM
- Building a global chemistry platform across Agro, Pharma, Electronics, EV, Aerospace & Defence.
- TTM Sales: βΉ2,534 Cr | +52%
- TTM Operating Profit: βΉ562 Cr
- Q1 FY27 Sales: βΉ655 Cr
- Q1 OPM: 25%
PHARMA + JAYHAWK OPTIONALITY
- Pharma business has scaled dramatically.
- Jayhawk adds US manufacturing capabilities along with exposure to Semiconductor, Defence & EV applications.
- Creates a potential bridge from specialty chemicals toward higher-value advanced materials and CDMO opportunities.
CAPACITY & OPERATING LEVERAGE
- βΉ3,700+ Cr fixed-asset base provides significant operating-leverage potential.
- Long-term customer relationships and qualification barriers can support sticky business.
- The key transition to watch:
CAPEX β UTILISATION β EBITDA β CASH FLOW β ROCE
KEY RISKS / FORENSIC WATCH
- PE: 80.7Γ
- ROCE: 7.36%
- Borrowings: βΉ1,867 Cr
- Other Liabilities: βΉ2,811 Cr
- Promoter Pledge: 21.8%
- High valuation and weak current capital efficiency leave limited room for execution disappointment.
WHAT NEEDS TO IMPROVE
- ROCE needs to move from ~7% toward 12%+.
- Free cash flow needs to become sustainably positive.
- Debt should decline alongside improving asset utilisation.
- Promoter pledge reduction would strengthen the balance-sheet quality of the thesis.
KEY TAKEAWAY
- Great business potential + powerful new growth platforms, but expensive valuation and balance-sheet risks.
- The investment thesis ultimately depends on whether the large asset base translates into higher utilisation, EBITDA, free cash flow and ROCE.
- Strong growth story, but deserves a serious forensic watchlist. | 1 692 |
| 6 |  +1Kabra Extrusiontechnik has packed several strategic moves into just eight days.
First, GEON announced that high-voltage battery-pack production for passenger cars would begin at Pune in September.
Then came three more developments:
β’ LOI from a top-three Indian two-wheeler manufacturer for two battery programmes
β’ Nomination from a leading passenger-vehicle manufacturer in Vietnam
β’ Approval for a Vietnam battery-pack facility involving investment of up to βΉ500 Cr
β’ βΉ141 Cr preferential equity issue to support the next growth phase
The underlying business is already shifting:
β’ Q1 FY27 revenue: βΉ124.5 Cr, up 44.8%
β’ GEON revenue: βΉ70.1 Cr, up 133.1%
β’ GEONβs revenue contribution: 56.3%
β’ Installed battery-pack capacity: 7 GWh
β’ Battery packs deployed: 400,000+
The annual report states:
βAt optimal levels, the existing facility can generate βΉ1,500+ crore revenue.β
But that is capacity potential not revenue guidance.
Customer names, order values, volumes and programme timelines remain undisclosed.
The story has moved from building capacity to winning customer programmes. The next test is converting those programmes into profitable, recurring revenue.
@Stockupdate9 | 1 471 |
| 7 |  8 TVS Group companies delivered 100-650% returns over 5 years, while 4 companies delivered 45-85%. Only 1 is negative from its IPO price but its business has improved significantly and is now on the cusp of strong earnings growth and margin expansion. | 1 608 |
| 8 |  Yasho Industries is set to grow 5X its EPS this year, driven by long-term commitments from various customers, and to double revenue within 2 years.
Worth the rally the company is experiencing right now. | 1 856 |
| 9 |  No text... | 1 926 |
| 10 | ELANTAS BECK INDIA | ELECTRIFICATION + SPECIALTY CHEMICALS
BUSINESS OVERVIEW
- Makes specialty chemistry that protects electrical equipment β wire enamels, insulating varnishes & resins, casting/potting compounds and electronic materials.
- Applications span motors, transformers, generators, pumps, appliances, automotive electronics, EVs and other electrical systems.
- CY25 revenue mix: Electrical Insulation ~81% | EERM ~19%.
STRONG MOAT & PRICING POWER
- Products are often a tiny part of the customer's total cost but are critical for equipment reliability.
- Failure of insulation can result in failure of the entire motor/electrical system.
- Products are qualified into customer manufacturing processes and can also be specified by OEMs.
- High cost of failure + qualification requirements + technical support = strong switching barriers.
- CY25 gross margin improved 36.9% β 38.1%, while EBITDA margin increased 19.3% β 20.3%, despite raw-material inflation.
EERM | HIGH-MARGIN MIX SHIFT
- EERM contributed only 19.4% of CY25 revenue but around 29% of segment profit.
- Higher margins make EERM an important driver of potential future mix improvement.
- Key thesis: gradually reduce dependence on conventional electrical-insulation products and increase exposure to differentiated, higher-value materials.
TECHNOLOGY & PRODUCT EXPANSION
- Started manufacturing 22 products acquired from Von Roll India, adding high-voltage resin and tape technologies.
- Absorbing global ELANTAS technologies including:
- VOC-free unsaturated polyester resin.
- High-voltage epoxy impregnating resin.
- Thixotropic epoxy resin for high-voltage wind generators.
- Expands the portfolio toward more specialised electrical and high-voltage applications.
EV + BESS + POWER ELECTRONICS
- Developing potting materials and thermal-interface materials for battery systems.
- Global R&D project for a high-thermal-conductivity adhesive for BESS targeted for absorption in 2027.
- Electrification increasingly requires advanced insulation, thermal management, protection and reliability β areas where ELANTAS is building capabilities.
CAPACITY EXPANSION
- Approved βΉ56 Cr Ankleshwar expansion.
- Plans to double solvent-recovery capacity.
- Working toward a new greenfield manufacturing facility at Bharuch.
- Additional capacity can support the company's expanding product pipeline.
CTC | POWER TRANSMISSION OPPORTUNITY
- CTC (Continuous Transposed Conductor) is used in high-power transformers.
- ELANTAS was able to scale CTC manufacturing within around 3 months when demand surged.
- Provides exposure to the growing transformer and power-transmission investment cycle.
THE BIGGER TRANSFORMATION
- The story is not simply:
India electrification β more wire enamel β more revenue
- The broader evolution is:
Core Insulation β High-Voltage Materials β Electronics β EVs β BESS β Advanced Power Transmission
- ELANTAS is attempting to move up the value chain by combining existing customer relationships, technical know-how and the global ELANTAS technology platform.
KEY THING TO WATCH
- Electrical Insulation still dominates the business.
- The key question is whether EERM and other higher-value applications can become a materially larger share of revenue and profit.
- Successful execution could reposition ELANTAS from a conventional insulation-chemical manufacturer toward a high-value materials partner for electrification, power infrastructure, electronics, EVs and energy storage.
Must JOIN
@Fundamental3 | 5 266 |
| 11 | DEEPAK NITRITE β CAPACITY + CUSTOMER VALIDATION
- βΉ1,400 Cr phenol/acetone project initially represented only a Stage 1 capex story.
- Before commissioning, customer outreach and seed marketing had already started showing encouraging demand.
- Indian phenol demand was also running stronger than originally assumed.
- Plant commissioned in November 2018.
- Utilisation crossed 80% within the first few months.
- FY20 operating cash flow subsequently reached ~βΉ765 Cr.
- Consolidated net debt/equity fell from 1.11x FY19 β 0.69x FY20 β 0.15x FY21.
- Key lesson: Demand validation + utilisation + debt reduction confirmed the capex-to-cash inflection.
VALIANT ORGANICS β APPROVAL-GATED CAPACITY INFLECTION
- Existing 4,800 MTPA chlorophenol plant was already operating near full utilisation.
- Expansion could increase capacity toward ~21,600 MTPA.
- Environmental approval was the major uncertainty.
- Existing utilisation had already validated demand.
- Balance sheet was virtually debt-free.
- Approval progress + capacity expansion + strong existing utilisation created the Stage 2 opportunity.
- Once approvals, commissioning and utilisation became obvious, much of the catalyst became priced in.
- Key lesson: Catalysts have an expiry date.
CG POWER β GOVERNANCE + BALANCE-SHEET INFLECTION
- CG Power had a viable industrial franchise trapped inside governance and balance-sheet problems.
- Tube Investments / Murugappa Group acquired control and infused fresh capital.
- Board and ownership changed.
- ~βΉ2,160 Cr debt claims were settled at ~βΉ1,000 Cr.
- Operational creditors and employee dues were addressed.
- Working-capital lines reopened.
- Customers had not disappeared; order book remained healthy.
- Credit rating moved from default to AA-.
- FY22 revenue subsequently reached βΉ5,561 Cr, +88%, while PAT before exceptional items reached βΉ405 Cr.
- Key lesson: In governance turnarounds, legal certainty comes first, liquidity second and earnings last.
TBZ β OWNERSHIP INFLECTION BUT OPERATING EVIDENCE STILL NEEDED
- GRT is acquiring control of TBZ, creating a potentially meaningful ownership change.
- GRT could bring procurement, inventory management, customer schemes and stronger retail execution.
- But operating evidence has not yet sufficiently confirmed the turnaround.
- Gold jewellery volumes declined from 3,424 kg FY23 to 2,249 kg FY26.
- FY26 operating cash flow was only ~βΉ30 Cr against PAT of ~βΉ202 Cr.
- Inventory and borrowings increased materially.
- Current setup is closer to Stage 1β1.5.
- Need volume growth, same-store growth, inventory improvement and cash-flow confirmation before calling it Stage 2.
ROYAL ENFIELD β DEMAND PULLED CAPACITY
- Demand exceeded supply before major capacity expansion.
- Long waiting periods demonstrated genuine product-market fit.
- Classic 350/500 and the new engine platform strengthened the product proposition.
- Management then invested to remove the production bottleneck.
- Oragadam plant started production in 2013 with 150,000-unit initial capacity.
- Motorcycle sales reached ~178,000 units in 2013 and production plans were raised further.
- Importantly, expansion was supported by a strong balance sheet rather than dangerous leverage.
- Key lesson: Demand pulling capacity into existence is much stronger than capacity searching for demand.
E2E NETWORKS β ASSET REGISTER BEFORE PROFIT EXPLOSION
- E2E was evolving from a generic cloud provider toward GPU infrastructure.
- GPU products appeared in the company's physical asset base and customer catalogue before becoming meaningful in reported profits.
- Computer equipment expanded significantly relative to the company's existing revenue base.
- Early capex was substantially supported by operating cash flow rather than excessive debt.
- The next critical evidence was utilisation and recurring customer revenue.
- Key lesson: Physical assets + product catalogue + customer commitments can reveal the next business before PAT does.
IEX β REGULATION BEFORE VOLUME
- IEX was already profitable; profitability itself was not the inflection.
- Regulatory changes increased the usefulness of exchange-based short-term electricity trading.
- Real-Time Market created additional opportunities for last-minute balancing.
- Existing network liquidity meant IEX could absorb the new market without massive incremental capital.
- Higher volumes therefore offered substantial operating leverage.
- Key lesson: Regulation can change the earnings trajectory before reported volumes reveal the full impact.
HOW TO DISTINGUISH A REAL INFLECTION FROM A TRAP
OPERATING CONFIRMATION
- Volumes growing faster than industry.
- Repeat orders / customer retention improving.
- Capacity utilisation crossing fixed-cost breakeven.
- Same-store sales / unit economics improving.
- New products becoming meaningful.
- Market share increasing without receivables exploding.
CASH FLOW / BALANCE-SHEET CONFIRMATION
- Receivable and inventory days remain stable or improve.
- Operating cash flow begins following EBITDA.
- Customer advances support the order book.
- Debt and interest burden decline.
- Expansion becomes increasingly self-funded.
- Incremental ROIC remains above cost of capital.
RED FLAG
- If reported P&L improves while cash conversion deteriorates materially, treat the claimed inflection with caution.
- Revenue growth financed by exploding receivables or inventory may not represent genuine improvement.
THE REPEATABLE PROCESS
- Identify what changed FIRST.
- Find at least 2 independent operating confirmations.
- Check what cash flow / balance sheet confirms.
- Understand what the P&L should show later.
- Define exactly what would invalidate the thesis.
- Finally, ask whether valuation still assumes the OLD earnings path.
THE IDEAL MULTIBAGGER SETUP
- Good underlying business.
- Leading indicators already improving.
- Two or more independent confirmations.
- Healthy cash flow / balance sheet.
- Earnings still look ordinary.
- Market expectations remain anchored to historical earnings.
- Clear runway for revenue + margin expansion.
- Valuation has NOT yet moved to Stage 4/5 expectations.
KEY TAKEAWAY
- The biggest asymmetry often sits at Stage 2: operating evidence is improving, cash/balance sheet confirms it, but earnings and market expectations have not yet caught up. | 3 513 |
| 12 | THE MULTIBAGGER INFLECTION POINT | HOW TO BUY BEFORE EARNINGS BECOME OBVIOUS
CORE IDEA
- A multibagger usually does not begin simply because a stock has a low P/E.
- It begins when the company's old earnings trajectory starts changing, while the market is still valuing the business using its historical revenue, margins and risks.
- The opportunity lies between hard operating evidence emerging and full market recognition.
- The objective is to identify the change BEFORE reported PAT makes the improvement obvious.
5 CONDITIONS FOR A REAL INVESTIBLE INFLECTION
- Business must be structurally relevant with meaningful long-term terminal value.
- A leading operating variable must genuinely change.
- At least 2 independent operating indicators should confirm the improvement.
- Cash flow / balance sheet should confirm that growth is genuine.
- Valuation should still reflect too much of the old earnings trajectory.
- If one of these is missing, it may simply be a story, cyclical recovery or good company at an expensive price.
WHY EARNINGS MATTER
- Long-term wealth creation ultimately requires earnings growth.
- Motilal Oswal's 25-year study showed aggregate price CAGR and PAT CAGR of ~17% among the 100 wealth creators studied.
- Small size alone does not create a multibagger.
- A small company still needs moat, cash conversion, governance and the ability to reinvest capital at attractive returns.
- An inflection must eventually convert into business quality.
THE TWO ENGINES OF A MULTIBAGGER
- Share Price = Revenue Γ Net Margin Γ P/E Γ· Diluted Shares.
- Returns can therefore come from revenue growth, margin expansion, valuation rerating and limited dilution.
- A powerful multibagger often combines EPS growth with P/E rerating.
- Example: if earnings become 3x and P/E expands from 12x to 24x, the stock can theoretically become ~6x.
- But P/E expansion should be the accelerator, NOT the main engine.
- Sustainable wealth creation ultimately requires earnings growth.
WHAT EXACTLY IS AN INFLECTION?
- An inflection is NOT simply the first strong quarter.
- It is the point where the probability of future earnings materially improves.
- P&L is generally a lagging indicator.
- Capacity utilisation, customer behaviour, orders, working capital, debt and other operating indicators can reveal the change much earlier.
- The best opportunity often appears one stage before earnings become obvious.
STAGE 1 β STORY ONLY
- Management announces capex, new products, TAM opportunity or ambitious FY30 targets.
- Customer validation is absent.
- Operating evidence is absent.
- At this stage, the investment case remains a possibility rather than an inflection.
STAGE 2 β LEADING EVIDENCE
- Capacity utilisation starts increasing.
- Customers begin placing repeat orders.
- Order book strengthens.
- Same-store sales improve.
- New products/formats start showing repeatable economics.
- Receivables remain controlled.
- Reported PAT may still look weak.
- This is generally the BEST ZONE for asymmetric risk-reward.
STAGE 3 β EARNINGS CONFIRMATION
- Revenue accelerates.
- Fixed costs get absorbed.
- EBITDA margins improve.
- Earnings growth becomes visible.
- Analyst/consensus estimates start increasing.
- Opportunity can still remain attractive if the runway is long, but valuation becomes increasingly important.
STAGE 4 β CONSENSUS RECOGNITION
- Company becomes widely discussed.
- Investors start valuing the stock using management's long-term targets.
- Growth story becomes consensus.
- Business may still remain excellent, but asymmetry becomes weaker.
STAGE 5 β EXTRAPOLATION
- Current margins are assumed to continue indefinitely.
- Competition and cyclicality are underestimated.
- Terminal valuation becomes increasingly aggressive.
- Even an excellent company can become a poor investment at this stage.
THE SWEET SPOT
- Stage 2 is generally where the biggest asymmetry exists.
- Enough evidence exists to show that something has genuinely changed.
- But earnings and valuation have not yet fully captured that change.
- Waiting for perfect numbers often means entering after the market has already recognised the inflection.
7 TYPES OF INFLECTION
1. DEMAND / MARKET SHARE
- First signal: volumes grow faster than the industry.
- Confirm through retention, repeat orders, pricing and competitor behaviour.
2. CAPACITY UTILISATION
- First signal: production crosses fixed-cost breakeven.
- Confirm through utilisation, contribution margin, customer demand and working capital.
3. NEW PRODUCT / FORMAT
- First signal: a small experiment becomes repeatable.
- Confirm through unit economics, maturity and payback period.
4. INDUSTRY CAPITAL CYCLE
- First signal: supply growth slows while demand remains healthy.
- Confirm through inventories, pricing, competitor shutdowns and capacity announcements.
5. BALANCE-SHEET REPAIR
- First signal: debt and interest burden start falling.
- Confirm through operating cash flow, refinancing and asset monetisation.
6. GOVERNANCE CHANGE
- First signal: ownership or capital allocation improves.
- Confirm through board changes, related-party cleanup and treatment of minority shareholders.
7. FORMALISATION / REGULATION
- First signal: market share shifts toward organised/compliant players.
- Confirm that regulation is actually enforced and economics remain attractive without subsidies.
CAPEX-TO-CASH INFLECTION
- During capex, cash leaves the business before revenue arrives.
- CWIP, debt, depreciation and interest rise while ROCE initially looks weak.
- Once the plant commissions and demand exists, utilisation starts increasing.
- Revenue can then grow faster than the asset base.
- EBITDA grows faster than revenue due to operating leverage.
- Operating cash flow eventually begins reducing debt.
- This transition from CAPEX β UTILISATION β EBITDA β CASH FLOW is one of the most powerful inflection setups.
4 QUESTIONS BEFORE BUYING A CAPEX STORY
- What physical capacity has actually been created?
- Who will buy the additional production?
- What contribution margin can the new capacity generate?
- How much working capital and maintenance capex will be required?
- Commissioning itself is NOT proof of demand.
- Order book itself is NOT proof of cash generation.
TRENT / ZUDIO β UNIT ECONOMICS BEFORE PROFITS
- The important evidence appeared at the store level rather than consolidated PAT.
- Zudio had 40 standalone stores by March 2019 and added 33 stores within one year.
- Mature stores crossed ~βΉ14,000 annual sales/sq ft.
- Individual stores required only ~βΉ3β4 Cr capital.
- Zudio revenue increased from βΉ118 Cr FY17 β βΉ144 Cr FY18 β βΉ204 Cr FY19.
- By FY20, standalone stores reached 80 and revenue increased to βΉ507 Cr.
- The real inflection was proving that a small, capital-efficient retail format could be replicated repeatedly.
- Key lesson: Store cohorts revealed the business model before consolidated earnings did.
BAJAJ FINANCE β CUSTOMER FUNNEL BEFORE THE PLATFORM BECAME OBVIOUS
- Consumer-durable financing became a low-cost customer acquisition engine.
- Consumer-durable deployment reached βΉ2,262 Cr in FY11, +118%, versus industry growth of ~31%.
- Around 9.69 lakh customers were acquired within one year through 2,000+ points of sale.
- Existing repayment behaviour allowed Bajaj Finance to cross-sell additional financial products.
- Receivables increased strongly while net NPA remained ~0.8%.
- Growth and asset quality improved together.
- Key lesson: The loan book showed why earnings growth could repeat before the P&L fully reflected it.
APOLLO FINVEST β LIVE STAGE 2 EXAMPLE
- Apollo Cash launched in October 2025.
- Within 8 months, it recorded ~2.36 lakh organic installations.
- ~32,000 loans were disbursed.
- Cumulative disbursement reached ~βΉ12 Cr.
- Customer acquisition happened without paid marketing.
- Product adoption provides early evidence, but underwriting quality is still unproven.
- The next confirmation must come from delinquencies, credit losses, repeat borrowing and contribution margins.
- Therefore, Apollo Finvest remains a Stage 2 candidate rather than a confirmed inflection. | 2 957 |
| 13 | EXICOM TELE-SYSTEMS | TRITIUM TURNAROUND + CRITICAL POWER SCALE-UP
BUSINESS & MOAT
- Exicom operates across two key businesses: Critical Power systems for telecom sites and EV charging hardware through India operations + US subsidiary Tritium.
- Critical Power contributed βΉ177 Cr in Q1 FY27, +73% YoY, while standalone EV charging revenue was βΉ61 Cr, +15% YoY.
- Exicom has >50% share in India's wallbox charger market and ~60% share in the BharatNet government fibre project.
- Deep qualification cycles and switching costs support the moat; telecom customers have worked with Exicom for ~30 years.
- Consolidated order book stood at βΉ1,400 Cr as of June 30, 2026.
INDIA BUSINESS β STRONGER GROWTH
- Standalone Q1 FY27 revenue was βΉ234 Cr, +58% YoY, with EBITDA of βΉ16 Cr.
- Standalone EBITDA margin improved to 8.8% from 5.8% YoY; gross margin was 29.1%.
- Hyderabad plant became fully operational in Q4 FY26 and triples production capacity.
- Production is shifting from Gurgaon to Hyderabad over the next 2β3 months, eliminating βΉ8.7 Cr of annualised parallel-run fixed costs.
- Critical Power exports expected to rise from ~8% of sales in Q1 FY27 to ~15% by FY27-end.
- BESS is expected to scale from near-zero to ~βΉ50 Cr revenue in FY27, supported by 15 MWh orders already won.
- India business could compound at 20β30%, supported by telecom tower additions and EV penetration.
TRITIUM β THE BIG TURNAROUND DRIVER
- Consolidated EBITDA turned positive in Q4 FY26 for the first time since Tritium acquisition.
- Tritium is targeting 3x revenue growth in FY27 and EBITDA breakeven by Q4 FY27.
- Q1 FY27 Tritium bookings reached $20.8 Mn, around 2x the previous quarterly average; backlog was ~$20 Mn as of July 1.
- Q1 FY27 Tritium revenue was ~$10.5 Mn; 3x FY27 growth implies roughly $120 Mn annualised revenue.
- TRI-FLEX and other new products are under trials with Fortune 100 companies.
- A successful hyperscaler qualification could create a $30β35 Mn FY28 revenue opportunity per product.
- A $30 Mn firm Fortune 50 purchase order has already been secured, with deliveries beginning January 2026; a second ~$30 Mn annual RFP is advanced.
- If product trials convert, FY28 Tritium revenue could potentially exceed $150 Mn.
COST & MARGIN INFLECTION
- Hyderabad consolidation should remove parallel-run costs and improve fixed-cost absorption.
- Consolidated EBITDA breakeven is expected in Q2/Q3 FY27, while Tritium targets breakeven in Q4 FY27.
- By mid-2028, management expects Hyderabad to be fully loaded, Tritium to reach triple-digit-million-dollar revenue and consolidated EBITDA margins to reach high-single digits or better.
- If Tritium executes as guided, consolidated EBITDA could potentially reach βΉ100β150 Cr by FY28.
- FY26 VRS and retention costs were largely one-offs, while current PAT losses reflect fixed-cost absorption during the scale-up phase.
ORDER BOOK & GROWTH VISIBILITY
- Consolidated order book has reached βΉ1,400 Cr.
- Tritium bookings are accelerating, providing an important leading indicator for the turnaround.
- New product launches during MayβJuly 2026 create additional FY28 upside if customer qualifications convert.
- Completed Hyderabad capex provides capacity for the next phase without requiring fresh equity dilution.
MANAGEMENT EXECUTION β MIXED RECORD
- Management had earlier guided 50% standalone revenue growth for FY26 but delivered only 19%.
- Hyderabad plant commissioning slipped from October 2025 to March 2026.
- However, consolidated EBITDA breakeven was achieved in Q4 FY26, reportedly a year ahead of the original Tritium timeline.
- August 2026 management commentary reiterated consolidated EBITDA breakeven in Q2/Q3 FY27 and Tritium breakeven in Q4 FY27.
KEY RISKS / KILL SHOT
- The biggest risk is Tritium customer qualification and product-trial conversion.
- Failure of hyperscaler trials or delays in new product launches could derail the 3x Tritium growth and Q4 FY27 breakeven targets.
- Semiconductor and copper supply-chain volatility remains a risk.
- Working capital could rise sharply through inventory and receivables.
- Consolidated debt is ~βΉ370 Cr, so execution must translate into EBITDA and cash-flow improvement.
- The key quarterly monitorable is Tritium bookings and progress toward the Q4 FY27 breakeven commitment.
KEY TAKEAWAY
- Tritium qualification + 3x revenue growth + Hyderabad scale-up could transform Exicom into a high-growth, profitable EV/critical-power platform. | 2 231 |
| 14 |  No text... | 2 798 |
| 15 | MOREPEN LABORATORIES | FROM API MANUFACTURER TO GLOBAL CDMO + HEALTHCARE PLATFORM
CURRENT BUSINESS
- Morepen is traditionally known for API manufacturing, with products such as Loratadine, Montelukast, Atorvastatin and other specialised APIs.
- The business is now expanding across multiple healthcare verticals:
- APIs / Global Generics
- CDMO / Contract Manufacturing
- Domestic Formulations
- Medical Devices & Diagnostics
- Global Markets
- Longer-term optionality includes complex molecules and next-generation manufacturing opportunities.
THE TRANSFORMATION STORY
- The potential re-rating is not simply about higher API sales.
- The larger opportunity is moving up the pharmaceutical value chain.
- API business: large-scale manufacturing, exports and global customers.
- Formulations: brands, distribution and domestic healthcare.
- Medical devices: installed base, consumables and recurring demand.
- If successfully executed, Morepen could evolve from an API manufacturer into a diversified pharmaceutical and healthcare platform.
CDMO β THE NEXT MAJOR GROWTH ENGINE
- FY27 could become an inflection year for the CDMO business.
- Secured a βΉ825 Cr multi-year CDMO mandate from a global pharma major.
- βΉ58 Cr of commercial dispatches already completed in Q1 FY27.
- Management guides for ~βΉ225 Cr supplies in Q2 FY27.
- CDMO could contribute 50%+ of total revenue by Q3βQ4 FY27.
- The program could potentially add ~50β60% to the existing core API business.
WHY CDMO MATTERS
- Moves the company from selling individual APIs toward higher-value contract manufacturing.
- Large pharma relationships can create recurring commercial volumes after successful validation.
- Revenue progression should follow:
- Customer onboarding
- Product validation
- Commercial manufacturing
- Scale-up
- The key question is now execution speed rather than order-book availability.
WHAT TO WATCH
- Conversion of the βΉ825 Cr mandate into actual recurring revenue.
- Q2 supplies versus the ~βΉ225 Cr management target.
- CDMO contribution reaching 50%+ of revenue.
- Ability to scale manufacturing without significant margin dilution.
- Further customer additions and movement toward complex molecules.
KEY TAKEAWAY
Morepen's CDMO ramp could shift the company from an API-led business toward a higher-value global pharma platform.
Stock Stats | Stock info | Infographics
@Stockinfo333 | 3 844 |
| 16 |  +1Morepen Laboratories: Can an old API company transform into a Global CDMO + Healthcare Platform? πMost investors know Morepen Laboratories for one thing: APIs. πThe company is one of India's established pharmaceutical ingredient manufacturers and has built capabilities in products such as: β Loratadine β Montelukast β Atorvastatin β Other specialised APIs π The company is now trying to build multiple growth engines: β APIs β CDMO / Contract Manufacturing β Domestic Formulations β Medical Devices & Diagnostics β Global Markets π And potentially, over the longer term: Complex molecules and next-generation manufacturing opportunities. π The question is no longer simply: "How fast can API sales grow?" The bigger question is: Can Morepen move up the pharmaceutical value chain? π Morepen operates across multiple healthcare verticals. The broad structure can be understood as: β Global Generics / APIs: Manufacturing active pharmaceutical ingredients. β Domestic Formulations: Selling pharmaceutical and healthcare products in India. β Home Health: Diagnostics and medical devices under brands such as Dr. Morepen. π This combination is important. Because each business has a different economic model. β API: Large-scale manufacturing + exports + global customers β Formulations: Brands + distribution + domestic healthcare β Medical devices: Installed base + consumables + recurring demand π The opportunity is therefore much broader than a single pharmaceutical segment. π The company could gradually move from being viewed as an: API manufacturer, to something much bigger: A diversified, higher-value pharmaceutical and healthcare platform. | 3 444 |
| 17 |  AKSHAR CHEM | CHINA SUPPLY DISRUPTION + SILICA EXPANSION
WHAT IS DRIVING THE STOCK
- Stock hit a fresh all-time high of βΉ407.
- Q1 FY27 PAT surged to βΉ15.2 Cr from just βΉ0.7 Cr YoY.
- H-Acid prices reportedly jumped from ~CNY45,000/t to ~CNY120,000/t following Chinese production disruptions.
- AksharChem has spare capacity in H-Acid and Vinyl Sulphone, allowing higher realisations without immediate major capex.
SECOND β AND MORE STRUCTURAL β TRIGGER
- Precipitated silica capacity expanded 50% to 18,000 MTPA.
- Tyre makers are increasingly adopting silica-based βgreen tyresβ.
- China+1 sourcing could create a longer-term demand opportunity.
- Unlike the H-Acid opportunity, silica could potentially become a more durable growth engine.
BUSINESS STRENGTHS
- 7.93 MWp + 2.4 MWp captive solar capacity.
- ~57% revenue from exports across 30+ countries.
- Added customers across Europe, Vietnam, Turkey, Taiwan and South Korea.
- ~82% repeat business indicates strong customer relationships.
THE BIG DEBATE β CYCLICAL OR STRUCTURAL?
- Q1 operating margin reached ~16%, and the market is increasingly pricing in sustained improvement.
- H-Acid price spikes can materially boost earnings if Chinese supply remains constrained.
- But if Chinese production normalises and H-Acid prices fall, the earnings benefit could reverse quickly.
- The silica expansion provides a potential structural offset to this cyclicality.
VALUATION / RISK
- At βΉ407, the stock trades at ~26x earnings.
- FY26 ROCE was only ~0.2%, highlighting how sharply the market is looking through historical profitability.
- At an all-time high, the margin of safety is limited.
- The key question is whether current earnings are a temporary chemical upcycle or the beginning of a sustainable recovery.
KEY MONITORABLES
- H-Acid pricing and Chinese supply situation.
- Sustainability of ~16% operating margins.
- Utilisation and realisations from spare H-Acid/Vinyl Sulphone capacity.
- Ramp-up of 18,000 MTPA precipitated silica capacity.
- New customer additions and repeat-order momentum.
KEY TAKEAWAY
H-Acid is the near-term earnings trigger, while silica could determine whether the recovery becomes structural. | 3 397 |
| 18 | Almost every electric motor and generator on earth needs a lamination stack. Few outside the industry have heard of the company that makes most of them in India.
That company has spent the last 4-5 years quietly converting itself from a single-product stamper into a vertically integrated engineering platform - adding precision machining, iron castings, and full sub-assembly capability through two external acquisitions and two group entity consolidations between FY23 and FY25.
It supplies traction motor cores to both Wabtec and Alstom - Both are the only primary OEMs for Indian Railway locomotive manufacturing tenders. Whoever wins the tender, the cores come from the same place. With Cummins, it is the anchor vendor for laminations used in data centre DG set stators and rotors. One of Indiaβs leading manufacturers and exporters of electrical steel laminations, with capacity at six plants across Telangana, Maharashtra, and Karnataka.
That company is Pitti Engineering Ltd - A Hyderabad-based electrical steel lamination manufacturer founded in 1983, and now an integrated platform spanning stamping, machining, casting, and sub-assembly under a single P&L. | 2 964 |
| 19 |  Textiles Value Chain , we are seeing profit pools emerge on both Spinners and Garmenting , especially UK facing
source: Nuvama
Swing trading | Positional Trading
@Wealthcreator7 | 3 100 |
| 20 |  No text... | 1 826 |
